Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 50 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 698,946 Ordinary […]